Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2024 issues

Mutations and manifestations: what’s known about VEXAS

August 2024—The recently discovered VEXAS syndrome is caused by somatic mutations in the UBA1 gene arising in bone marrow stem cells. VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome was discovered when National Institutes of Health researchers identified deleterious mutations in ubiquitin-related genes. In a retrospective observational study published last year, Beck, et al., evaluated UBA1 variants in exome data from the Geisinger MyCode Community Health Initiative, a health-system-based cohort of patients who provide samples for broad research use. Clinical phenotypes were determined from Geisinger EHR data spanning four to 25 years. UBA1 variants were found in one in 13,591 unrelated individuals, one in 4,269 men older than 50, and one in 26,238 women older than 50.

AP lab panel on LDTs, digital path, workforce

August 2024—Digital pathology, FDA oversight of laboratory-developed tests, and the workforce shortage took center stage when CAP TODAY publisher Bob McGonnagle convened a roundtable online to talk about anatomic pathology laboratories. The shortage of pathologists, in particular, “is even greater than one might realize because of generational expectations around work-life balance,” said Andrew Bellizzi, MD, who applauds such balance but notes its significance. Their June 18 conversation follows.

Cytopathology in focus—Use of cytologic material for ancillary studies in respiratory pathology: Begin with the end in mind

August 2024—Case. A 58-year-old female patient undergoes robotic endobronchial ultrasound-guided fine-needle aspiration for a peripherally located right upper lobe stellate-shaped lung lesion with ground-glass opacification. Rapid onsite evaluation (ROSE) assessments were adequate on four Diff-Quik (DQ) smears that were prepared for evaluation. One slide was cover-slipped for diagnostic purposes and the remaining slides were retained, uncovered. The cytopathologist requested additional material for further ancillary studies. The needle was rinsed in CytoLyt solution used to prepare a cell block from the cell pellet, and the residual supernatant was stored (at -80°C) for possible future molecular studies. The cell block cellularity was adequate, and the malignant cell population represented 50 percent of the sampled cells.

Cytopathology in focus: Reporting salivary gland cytopathology—what’s new in Milan ed. 2?

August 2024—The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is a widely endorsed and increasingly adopted standardized reporting system for salivary gland fine-needle aspiration biopsy specimens. The inaugural edition published in 2018 was inspired by the Bethesda cervicovaginal and thyroid reporting systems. The MSRSGC sought to facilitate clear and consistent communication between pathologists and the clinical team, thereby enhancing patient-centered decision-making and therapeutic interventions and assisting inter- and intralaboratory comparisons.

Cytopathology in focus—Low-grade pancreatic neuroendocrine tumors in small samples: Grading challenges

August 2024—Two to five percent of pancreatic tumors are pancreatic neuroendocrine neoplasms, of which more than 90 percent are well-differentiated pancreatic neuroendocrine tumors (PanNETs). The current World Health Organization classification stratifies PanNETs into three histological grades based on mitotic count and Ki-67 proliferation index. Low-grade PanNETs (grades one and two) are morphologically indistinguishable and have characteristic neuroendocrine cytomorphologic features: a dispersed/loosely cohesive smear pattern composed of small-to-medium monomorphic cells with occasional plasmacytoid appearance; amphophilic, granular, or vacuolated cytoplasm; round nuclei; and coarse salt-and-pepper chromatin.

From the President’s Desk

August 2024—The CAP has been expanding its international footprint in recent years, and I hope to accelerate that trend during my presidency. The reason is simple: The CAP has established the world standard in quality for clinical laboratories, and it is our responsibility to share that standard as broadly as we can to improve care for patients everywhere in the world.

Clinical pathology selected abstracts

August 2024—Social media, including websites and platforms such as Facebook, Instagram, and X (formerly Twitter), are a dominant way to consume news and entertainment and have significant societal impact. Social media use in medicine, including pathology, is widespread and has been associated with numerous benefits. The medical industry generally has encouraged the professional use of social media, despite its potential harm. The approaches of various medical disciplines to social media have included support for early adoption, publication of how-to guides, enthusiastic backing by professional organizations, and formulation of guidelines to temper usage. The authors conducted a study to identify motivating forces and premises that underpin physicians’ adoption of social media for professional uses.

Anatomic pathology selected abstracts

August 2024—Emerging data suggest a correlation between T1 bladder cancer subcategorization, or substaging, and oncological outcomes. The International Society of Urological Pathology held a 2022 consensus conference on issues in bladder cancer, in Basel, Switzerland, in which it tasked a working group with making recommendations for T1 subcategorization of transurethral bladder resections. To this end, the ISUP developed and circulated a survey to its membership querying approaches for subcategorizing T1 bladder cancer. The survey focused on clinical relevance, pathological reporting, and endorsement of T1 subcategorization in the daily practice of pathology. Approximately 40 percent of respondents to the pre-meeting survey indicated that they do not routinely report the T1 subcategory.

Molecular pathology selected abstracts

August 2024—Alzheimer disease is genetically intricate and involves rare and common genetic variants. Early-onset autosomal dominant Alzheimer disease (ADAD) is caused by mutations in the APP, PSEN1, and PSEN2 genes, while variants in numerous other genes contribute to the risk of developing late-onset Alzheimer disease, with APOE considered the most significant risk factor. APOE4 homozygotes face a lifetime risk of Alzheimer disease dementia of up to 60 percent by age 85, significantly higher than that of heterozygotes or noncarriers of the gene. The predictability of outcomes in APOE4 homozygotes has not been previously studied, limiting the application of statistical methods used in ADAD for APOE4 research. The predictable sequence of pathological, biomarker, and clinical changes in ADAD and Down syndrome has offered insights into Alz­heimer disease pathophysiology.

Q&A column

August 2024
Q. I have been tasked with doing a quality assurance review comparing automated differential results to the manual differential done on the same patient. Do you have recommendations regarding acceptable analytical criteria? Read answer.
Q. Can activated clotting time results handwritten by a perfusionist be sent to the laboratory to be entered into the laboratory information system? Read answer.

MARKETPLACE

TRENDING